Insulin therapy in type 2 diabetes patients failing oral agents: Cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US

Joshua A. Ray, W. J. Valentine, S. Roze, I. Nicklasson, D. Cobden, Philip Raskin, A. Garber, A. J. Palmer